尼克洛萨米德调节人肺动脉光滑肌细胞中的表型切换和炎症反应
Yuwen Lu1, Xiaogan Liang1, Jingwen Song1
1Department of Cardiology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433, China.
尼克洛萨米德 (NCL) 有效地抑制肺动脉光滑肌肉细胞的增殖和迁移,这是肺动脉高血压 (PAH) 的关键因素. 这种重新设计的药物还可以减少炎症,这表明它有可能成为一种新的PAH治疗方法.
科学领域:
- 心血管生物学 心血管生物学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 肺动脉光滑肌细胞 (PASMC) 的增殖和迁移是肺动脉高血压 (PAH) 中肺血管重塑的核心.
- 尼克洛萨米德 (NCL) 是一种杀虫剂,调节细胞过程,但其对PASMC表型和PAH炎症的影响尚不清楚.
研究的目的:
- 研究尼克洛萨米德 (NCL) 对肺动脉平滑肌细胞 (PASMC) 增殖,迁移,表型转换和炎症反应的影响.
- 探索尼克洛萨米德 (NCL) 作为肺动脉高血压 (PAH) 的治疗剂的重新利用潜力.
主要方法:
- 细胞增殖试验,流细胞测量,伤和穿孔试验被用来评估PASMC的增殖和迁移.
- 西方斑分析被用来评估与细胞周期,表型,信号通路 (P38/STAT3) 和炎症 (VCAM-1,ICAM-1,NLRP3炎症体) 相关的蛋白质表达.
- 进行了巨细胞粘附测试,以检查NCL对炎症细胞招募的影响.
主要成果:
- 尼克洛萨米德 (NCL) 显著抑制了PDGF-BB诱导的PASMC扩散和迁移,以剂量依赖的方式.
- 在PASMC中,NCL促进了G1阶段的停止和亡,同时恢复了光滑肌细胞表型标记物 (SMA,SM22,calponin).
- 通过减少巨细胞粘附,VCAM-1/ICAM-1表达和抑制NLRP3炎症酶激活,NCL抑制了TNFα诱导的炎症反应.
结论:
- 尼克洛萨米德 (NCL) 对PASMCs表现出多方面的影响,控制增殖,迁移,表型切换和炎症.
- 这些发现表明,尼克洛萨米德 (NCL) 作为治疗肺动脉高血压 (PAH) 的重新定位的治疗策略具有显著的前景.
更多相关视频
08:28Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro
Published on: February 15, 2022
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
相关概念视频
Nitric Oxide Signaling Pathway
Antihypertensive Drugs: Vasodilators
Antihypertensive Drugs: Action of Calcium Channel Blockers
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
